Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80
Organisation › Details

Erytech Pharma S.A. (Euronext Paris: ERYP, Nasdaq: ERYP)

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of first-line triple-negative breast cancer. An investigator-sponsored Phase 2 study in acute lymphoblastic leukemia was recently completed in the Nordic countries of Europe. Eryaspase is not approved in any country. ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States at its GMP manufacturing site in Princeton, New Jersey, USA. ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes. *

 

Period Start 2004-01-01 established
  Group Erytech (Group)
Products Industry Graspa®
  Industry 2 Erycaps® platform
Persons Person Beyen, Gil (Erytech 2012– CEO before TiGenix 201112 CBO + before CEO + Co-founder)
  Person 2 Soyer, Eric (Erytech 201509– CFO + COO before EDAP-TMS)
     
Region Region Lyon
  Country France
  Street 60 avenue Rockefeller
Bâtiment Adénine
  City 69008 Lyon
  Tel +33-4-7874-4438
    Address record changed: 2020-12-02
     
Basic data Employees B: 11 to 50 (2014-10-22)
  Currency EUR
  Cash 165,400,000 (2018-06-30)
     
    * Document for �About Section�: Erytech Pharma. (1/4/21). "Press Release: Erytech to Present at the LifeSci Partners 10th Annual Healthcare Corporate Access Event". Lyon & Cambridge, MA.
     
   
Record changed: 2021-01-05

Advertisement

Picture [iito] Made Without Love 650x80px

More documents for Erytech (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Network in German Capital Region 650x80px




» top